Key result
Regnase-1 gene therapy improves elastin architecture and limits aortic dilation in Marfan syndrome models.
Why the study?
Thoracic aortic aneurysm rupture or dissection remains the leading cause of death in Marfan syndrome, and whether vascular overexpression of regnase-1 protects against aneurysm progression was unknown.
Does AAV-mediated regnase-1 overexpression prevent aortic aneurysm progression in a model of Marfan syndrome?
Does AAV-mediated regnase-1 overexpression prevent aortic aneurysm progression in a model of Marfan syndrome?
Targeting proinflammatory responses by overexpressing regnase-1 in the aortic wall represents a potential novel gene therapy approach to halt thoracic aortic aneurysm progression in Marfan syndrome.
Hypothesis-generating for AAV-regnase-1 therapy in Marfan aortopathy; human trials required before clinical consideration.
Rupture or dissection of thoracic aortic aneurysms is still the leading cause of death for patients diagnosed with Marfan syndrome. Inflammation and matrix digestion regulated by matrix metalloproteases (MMPs) play a major role in the pathological remodeling of the aortic media. Regnase-1 is an endoribonuclease shown to cleave the mRNA of proinflammatory cytokines, such as interleukin-6. Considering the major anti-inflammatory effects of regnase-1, here, we aimed to determine whether adeno-associated virus (AAV)–mediated vascular overexpression of the protein could provide protection from the development and progression of aortic aneurysms in Marfan syndrome. The overexpression of regnase-1 resulted in a marked decrease in inflammatory parameters and elastin degradation in aortic smooth muscle cells in vitro . Intravenous injection of a vascular-targeted AAV vector resulted in the efficient transduction of the aortic wall and overexpression of regnase-1 in a murine model of Marfan syndrome, associated with lower circulating levels of proinflammatory cytokines and decreased MMP expression and activity. Regnase-1 overexpression strongly improved elastin architecture in the media and reduced aortic diameter at distinct locations. Therefore, AAV-mediated regnase-1 overexpression may represent a novel gene therapy approach for inhibiting aortic aneurysms in Marfan syndrome.
No takes yet. Share an insight, caveat, or question.
Noormalal et al. (2023) studied Marfan syndrome. AAV-mediated regnase-1 overexpression vs. AAV-EGFP control was evaluated on Elastin architecture (islands of damage) and aortic diameter. AAV-mediated regnase-1 overexpression improved elastin architecture and reduced aortic diameter in a murine model of Marfan syndrome by decreasing proinflammatory cytokines and MMP expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: